Nanomedicine – challenge and perspectives
By K. Riehemann, Stefan W. Schneider, T. Luger, B. Godin, Mauro Ferrari, H. Fuchs. Angewandte Chemie, 2009
1,207 citations recorded by the source corpus.
Nanomedicine introduces nanotechnology concepts into medicine and thus joins two large cross disciplinary fields with an unprecedented societal and economical potential arising from the natural combination of specific achievements in the respective fields. The common basis evolves from the molecular scale properties relevant in the two fields. Nanoanalytical tools such as local probes and molecular imaging techniques, allow us to characterize surface and interface properties at a nanometer scale at predefined locations, while elaborated chemical approaches offer the opportunity for the control and addressing of surfaces e. g. for targeted drug delivery, enhanced biocompatibility and neuroprosthetic purposes. This commonality opens a wide variety of economic fields both of industrial and clinical interests. However, concerns arise in this cross disciplinary area about toxicological aspects and ethical implications. This review gives an overview of selected recent developments of nanotechnology applied on medical objectives.
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/509508362c5fb440d35c061685d28bd59d7f6ceb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Biomedical Engineering
- Robert Langer
- Itamar Willner
- Brian P. Timko
- G. Storm
- Ali Khademhosseini
- E. Drăgan
- V. Mohanraj
- Y. Chen
In Molecular Biology
Citations in the corpus
- DNA computing circuits using libraries of DNAzyme subunits. (2010, methodology): “Figure 3d presents a cascade of YES2AND2InhibAND gates using a library of DNAzyme subunits (3), (4) and (19)–(22), the caged substrates as duplexes (15)/(16) and (17)/(18), the fluorophore-quencher-functionalized substrate (5), and inputs I5 (23), I6 (24) and I7 (25).”
- Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, result): “…debate about whether ligand-targeted NNMs are capable of significantly enhancing NNM accumulation at target sites over non-targeted NNMs (passive-targeting), with conflicting results reported in the literature (Ferrari, 2005; Puri et al., 2009; Riehemann et al., 2009; van der Meel et al., 2013).”